What Are Nitazenes—and Why They Scare Experts More Than Fentanyl
Nitazenes are a class of synthetic opioids first created in the 1950s that can be up to 40 times more potent than fentanyl. Never approved for medical use, they are now infiltrating illegal drug supplies worldwide, complicating overdose treatment and challenging law enforcement.
A Forgotten Lab Compound Returns
In the late 1950s, a Swiss pharmaceutical company synthesized a family of compounds called benzimidazole-opioids, better known today as nitazenes. Researchers were hunting for powerful painkillers, but the drugs proved far too dangerous for human use. They were shelved and largely forgotten for decades. Now, more than sixty years later, nitazenes are resurfacing—not in hospitals, but in street drugs sold across North America, Europe, and Australia.
How Nitazenes Work
Like all opioids, nitazenes bind to mu-opioid receptors in the brain, triggering pain relief, euphoria, and—at higher doses—life-threatening respiratory depression. What sets them apart is sheer potency. The most studied compound, etonitazene, is roughly 1,000 times more potent than morphine and up to 20 times more potent than fentanyl. Other variants such as isotonitazene and protonitazene fall at different points on the scale, but even the weakest nitazenes rival fentanyl in strength.
This extreme potency means a quantity invisible to the naked eye can cause a fatal overdose. For illicit manufacturers, that also means a tiny amount of raw material can produce enormous quantities of product, making nitazenes cheap and easy to traffic.
Why They're Spreading
Several factors fuel the rise of nitazenes. First, they are structurally distinct from fentanyl, which means many existing drug regulations and scheduling controls do not cover newer analogues. Chemists can tweak the molecular structure to create variants that temporarily fall outside controlled substance lists. Second, precursor chemicals are relatively accessible and synthesis is straightforward compared to plant-derived opioids like heroin.
Critically, most users do not know they are taking nitazenes. The compounds are routinely mixed into counterfeit pills, pressed to look like oxycodone or other prescription drugs, or blended into heroin and fentanyl supplies. The European Union Drugs Agency reports that nitazenes have been mis-sold as heroin in outbreaks across France, Ireland, and the United Kingdom.
The Toll So Far
Nitazenes first appeared in street drugs in Europe around 2019. Since then, the human cost has mounted rapidly. In the UK, nearly 200 deaths involved a nitazene in 2024—almost four times the number recorded in 2023. Estonia has been hit especially hard: in 2023, nitazenes were identified in 48 percent of all drug-related deaths in the country.
In the United States, the DEA reports nitazene detections in overdose deaths across more than 30 states, with laboratory data showing a 17 percent rise in nitazene findings among fentanyl-positive samples between 2023 and 2024.
Why Treatment Is Harder
Naloxone (brand name Narcan), the standard opioid overdose reversal drug, still works against nitazenes—but often not well enough. Because nitazenes bind so tightly to opioid receptors, bystanders and paramedics may need to administer multiple doses of naloxone, and the respiratory depression caused by nitazenes can outlast naloxone's effects. Another complication: many nitazenes do not appear on standard toxicology screens, meaning emergency physicians may not immediately recognize what they are treating.
The Regulatory Race
Governments are scrambling to keep pace. In August 2025, the DEA temporarily placed two newer variants—N-pyrrolidino metonitazene and N-pyrrolidino protonitazene—into Schedule I, joining seven other benzimidazole-opioids scheduled months earlier. In the U.S. Congress, the Nitazene Control Act aims to permanently schedule the entire class of benzimidazole-opioids rather than playing catch-up with each new analogue.
The United Nations Office on Drugs and Crime has also called for a coordinated global response, warning that nitazenes' low production cost and regulatory evasion make them a persistent, borderless threat.
What Comes Next
Experts stress that nitazenes are not replacing fentanyl overnight, but they represent the next evolution in an illicit drug supply that keeps growing more potent and more unpredictable. For public health systems, the priorities are clear: expand access to naloxone and train users to administer multiple doses, upgrade drug-checking services to detect nitazenes, and push for class-wide scheduling that stays ahead of clandestine chemists. The lesson of the fentanyl crisis—that a more potent synthetic can transform a drug epidemic almost overnight—makes early action on nitazenes urgent.
